14 results about "Hypodermic injection" patented technology

A medical instrument holder includes a base block configured to removably mount to a placement surface, and has prongs extending therefrom. A receiving block formed of soft and resiliently flexible material, such as an elastomeric foam, may be impaled on the prongs. A medical instrument (such as a syringe or scalpel) may be inserted into the receiving block, thereby effectively removably holding the medical instrument with respect to the placement surface. The receiving block may be discarded after use, and replaced with another receiving block for subsequent use. The holder is particularly useful for receiving the cap of a hypodermic syringe within the receiving block, allowing the syringe to be held in a ready-to-use location, and allowing one-handed removal of the syringe from the cap grasped by the receiving block.

A dosage verification system for use prior to administering an injection of a medicinal fluid drawn into the fluid chamber of a medical syringe, the system comprising a medical syringe having a barrel with an outwardly facing, flat indicia display surface, a plunger having a plunger seal disposed inside and slidably engaging an inwardly facing wall of the barrel and a plunger handle projecting rearwardly from the barrel, and a hypodermic needle projecting forwardly from the barrel, all in combination with an imaging device configured to view and selectively capture, store or transmit a digital image of the plunger position relative to the barrel when a dose of the medicinal fluid is drawn into the fluid chamber of the barrel prior to an injection to verify and provide a record of the dosage drawn, and to alert a user prior to injection when an incorrect dosage is drawn into the fluid chamber of the syringe.

The invention discloses a preparation method and application of carassius auratus rahn aquatic OmpA gene cloning and prokaryotic expression as well as a polyclonal antibody. The preparation method comprises the following steps: culture and DNA amplification of rahn aquatic, design of an OmpA primer, gene cloning and prokaryotic expression, back multi-point subcutaneous injection of an immune rabbit, heart blood sampling and preparation of the polyclonal antibody. The invention further provides OmpA protein prokaryotic expression and protein purification, preparation of OmpA polyclonal antiserum and application of fish bodies. According to the invention, a rahnella aquatilis OmpA gene is cloned, a specific Hind III and EcoR1 double-enzyme digestion primer sequence OmpA-1F / OmpA-1R is designed, a prokaryotic expression vector pET32a-OmpA is constructed, high-immunogenicity OmpA protein is obtained through purification, OmpA specific multi-antibody serum is prepared, and the OmpA specific multi-antibody serum can be used for preparing the multi-antibody serum. The OmpA polyclonal antibody can be used for detecting and positioning the expression application of rahnella aquatica OmpA protein in crucian carp bodies through bidirectional agar diffusion, an immunoblotting method and an immunohistochemical method, and provides a reference basis for research and development and application of rahnella aquatica subunit vaccines and a molecular diagnosis technology as well as immune prevention and control of infectious diseases of the rahnella aquatica subunit vaccines and the molecular diagnosis technology.

The utility model discloses a subcutaneous injection auxiliary device which comprises a needle cylinder, a detachable side cover, an automatic booster, a clamping piece and an adjustable sleeve. A pre-filled syringe is placed in the needle cylinder, and a needle head of the pre-filled syringe extends out of the front end of the needle cylinder; the clamping piece is arranged on the inner wall of the needle cylinder and is used for fixing the pre-filled syringe; the automatic booster is arranged at the inner rear end of the needle cylinder, meanwhile, an injection button is arranged on the outer end face of the rear end of the needle cylinder and used for starting the automatic booster, a piston handle clamping part is arranged at the front end of the automatic booster, and the piston handle clamping part can manually move forwards to be matched with a piston handle of the pre-filled syringe; the detachable side cover is detachably connected with the cylinder wall of the needle cylinder; the adjustable sleeve is arranged at the front end of the needle cylinder, and the extending length is adjustable. The self-service subcutaneous injection auxiliary device can assist home persons in completing subcutaneous injection through self-service operation.

According to the portable integrated hypodermic injector, a disinfection layer is arranged on the uppermost portion of a patch injector, the disinfection layer and a nursing layer and is arranged in a lower shell, after an upper cover sealed on the upper portion of the lower shell is detached, the disinfection layer can be taken out firstly, a user can be reminded to conduct disinfection firstly, and then the disinfection layer can be taken out; the nursing layer is arranged on the lower side or the upper side of the patch injector, and when the nursing layer is arranged on the upper side of the patch injector, the nursing layer and the patch injector are of a detachable integrated structure, so that the nursing layer and the patch injector can be taken out at the same time, and a user can be reminded to inject first and then nurse; the patch injector, the disinfection layer and the nursing layer are arranged at the positions, so that a patient can be reminded to use the patch injector according to the sequence of disinfection, injection and nursing as much as possible, the treatment standardization is improved, the injection-related infection rate is reduced, and the patch injector is small in size and convenient to carry.

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

The present application relates to the field of biological materials, in particular to a preparation method and application of GMS@EVs microspheres loaded with SNAP-VHH fusion protein. The present application constructs a gelatin microsphere delivery system (GMS@EVs) with capture and slow-release functions. The system specifically and efficiently captures CD9-positive exosomes secreted by mesenchymal stem cells through the stable fixation of SNAP-VHH fusion protein on the surface of gelatin microspheres, and realizes the efficient extraction of CD9-positive exosomes from the culture supernatant of mesenchymal stem cells. The present application provides specific reaction sites for the fixation of SNAP-VHH fusion protein by grafting O6-[4-(aminomethyl)benzyl]guanine on the gelatin microspheres, so that the SNAP-VHH fusion protein is stably loaded on the gelatin microspheres. Through experiments, the GMS@EVs microspheres prepared by the present application have controllable slow-release properties for exosomes, and still maintain significant fluorescence signals 48 hours after subcutaneous injection in nude mice, which is at least 16 times longer than the slow-release time of free exosomes (30 minutes of rapid diffusion), realizing the sustained release of exosomes in the local wound and enhancing the durability of the therapeutic effect.

The hypodermic needle is described as having a proximal end, a distal end having a tissue-piercing tip, and a lumen extending from the proximal end to the distal end. The elongate body may have a channel formed in its outer surface. The channel may be concave or formed in the outer wall. The portion having the channel may maintain a circular lumen, or the lumen may be non-circular or conform to the shape of the channel. Additionally, the elongate body may have a flattened portion along its length. The flattened portion may be at the distal-most portion of the elongate body extending proximally from the distal tip. The elongate body may also include a notch formed in the outer wall to communicate with the lumen or open to the lumen. The opening of the notch may traverse the lumen or be aligned with the lumen.

The invention discloses a preparation method and application of a rahnella aquatica OmpW protein expression and polyclonal antibody. The preparation method comprises the steps of culture and DNA amplification of rahnella aquatica, OmpW primer design, gene cloning and prokaryotic expression, back multi-point subcutaneous injection immunization rabbit, heart blood sampling and preparation of the polyclonal antibody. The invention also provides OmpW protein prokaryotic expression and protein purification, preparation of OmpW multi-antiserum and application of fish bodies. According to the invention, a rahnella aquatilis OmpW gene 633bp is cloned, a specific Hind III and EcoR I double-enzyme digestion primer sequence OmpW-F / OmpW-R is designed, a prokaryotic expression vector pET32a-OmpW is constructed, high-immunogenicity OmpW protein is obtained through purification, OmpW specific multi-antibody serum is prepared, and the OmpW specific multi-antibody serum can be used for preparing the multi-antibody serum. The OmpW polyclonal antibody can be used for detecting and positioning the expression application of the rahnella aquatica OmpW protein in a crucian carp body through bidirectional agar diffusion, an immunoblotting method and an immunohistochemical method, and provides a reference basis for research and development and application of rahnella aquatica subunit vaccines and a molecular diagnosis technology as well as immune prevention and control of infectious diseases of the rahnella aquatica subunit vaccines and the molecular diagnosis technology.

A die press apparatus and method of operating to fabricate vascular access needles having one or more complex shapes at different locations at or adjacent to or proximal to a tissue penetrating tip along with features along one or more positioned spaced along the body of the needle. In some specific needle configurations, the features are specifically positioned and shaped to cooperate with an article used with the needle such as a handle, catheter, guide element, valve, seal or other component of a vascular access system.

In the field of medical sharp instruments, particularly in the field of subcutaneous injection needles, an improved needle assembly is needed. A needle assembly (10, 80, 100, 110, 120, 130) for engagement with a syringe (58, 90) having an elongate hollow syringe body (56) within which a plunger (34, 88) is slidably received includes a needle assembly body (12) having a hypodermic needle (14) coupled with the needle assembly body to extend from a distal end (16) of the needle assembly body. The needle assembly (10, 80, 100, 110, 120, 130) also includes an actuator valve (18, 132) movably received within the needle assembly body (12) and formed to define a propellant storage volume (22, 122). The actuator valve (18, 132) is movable between a closed position, in which propellant is held under pressure in the propellant storage volume (22, 122), and an open position, in which propellant is released from the propellant storage volume to shield the needle (14).

In the field of drug delivery methods and devices, improved closed system transfer devices are required. A closed system transfer device (10) includes a syringe (12) having an elongate hollow syringe body (14) within which a plunger (16) is slidably received to define medicament chambers (18) of different sizes depending on the extent of insertion of the plunger within the syringe body (18). The closed system transfer device (10) also includes a needle assembly (28; 300) having a needle assembly body (30) to which the hypodermic needle (32) is securely secured. The needle assembly body (30) is coupled with the syringe body (14) to maintain an internal conduit (40) of the hypodermic needle (32) in fluid communication with the drug chamber (18). In addition, the closure system transfer device (10) also includes a shroud assembly (42) having a shroud body (44). The shroud body (44) is movably coupled with the syringe body (14), whereby the shroud assembly (14) is selectively operable to enclose the needle (32). The shroud body (44) and the syringe body (14) include mutually cooperating formations to constrain movement of the shroud assembly (42) relative to the syringe (12) through a series of positions (200, 210, 220, 230, 240, 250, 260) corresponding to different operating conditions of the device (10).

The invention discloses a construction method of a nude mouse ovarian cancer subcutaneous transplantation tumor model, and relates to the technical field of biomedicine. The method comprises the following steps: (a) culturing a first generation of ovarian cancer transplantation tumor in a first batch of nude mice by a cell suspension subcutaneous injection method; (b) obtaining the first-generation transplanted tumor tissue obtained in the step (a), and preparing the first-generation transplanted tumor tissue into a solid tumor block suitable for transplantation; and (c) transplanting the solid tumor block prepared in the step (b) to the subcutaneous part of a second batch of nude mice to construct a subculture transplantation tumor model. Compared with a traditional cell suspension direct injection method, the adopted subculture solid tumor mass transplantation method can remarkably improve the tumor formation success rate and the tumor growth speed. The model constructed by the method retains more tumor interstitial components, is closer to the biological characteristics of clinical tumors, and provides a more stable and reliable in-vivo experimental platform for drug screening, pathogenesis research and personalized treatment of ovarian cancer.